Aragon Announces Key Strategic Hire

Aragon Announces Key Strategic Hire 
Paul Cleveland Joins as EVP of Corporate Strategy and Chief Financial
Officer 
SAN DIEGO, CA -- (Marketwire) -- 02/11/13 --  Aragon Pharmaceuticals
Inc., a leader in developing drugs for hormone driven cancers, today
announced that Paul Cleveland has joined the company as Chief
Financial Officer and Executive Vice President, Corporate Strategy.
In this role, Mr. Cleveland will be responsible for the company's
finance, legal, investor relations and business development matters. 
"We are pleased to welcome Paul to Aragon," said Richard A. Heyman,
Ph.D., President and CEO of Aragon Pharmaceuticals. "His extensive
experience across business development, legal, and finance in public
and private companies will add tremendous value to the company. Paul
joins Aragon at an optimal time, strengthening our management team
and corporate development capabilities, as we continue to progress
our pipeline, including ARN-509 into late stage clinical trials."  
Prior to Aragon, Mr. Cleveland spent two years as a General Partner
and Chief Operating Officer at Mohr Davidow Ventures. Previously, he
spent five years at Affymax Inc., where he served as Executive Vice
President, Corporate Development and Chief Financial Officer, leading
the Company through its successful public o
ffering in 2006. Prior to
Affymax, Mr. Cleveland was a Managing Director at JP Morgan (formerly
Hambrecht & Quist), where he served as Head of West Coast Mergers and
Acquisitions. He also brings to Aragon 15 years of experience as a
practicing attorney, most recently as a Partner within the Corporate
Group at Cooley Godward in Palo Alto, CA. Mr. Cleveland has served as
a member of the Board of Directors of three biotechnology companies,
and currently serves as a member of the Board of Sangamo Biosciences,
Inc. 
"I am excited to be joining such a high quality team as the company
transitions to its next stage of corporate growth," said Mr.
Cleveland. "There is nothing more gratifying than helping to develop
treatment options for cancer patients in need." 
About Aragon Pharmaceuticals 
Aragon Pharmaceuticals is focused on the development of 2nd
generation anti-hormonal agents for hormone-driven cancers. The
company's portfolio of small molecule therapeutics is based upon
pioneering research identifying key molecular events that lead to
drug resistance to traditional anti-hormonal therapies. This work has
broad implications for the development of breakthrough medicines for
prostate cancer and other hormone-dependent cancers such as breast,
ovarian and endometrial cancer. Aragon Pharmaceutical's most advanced
compound, ARN-509, is an androgen receptor antagonist that is
currently being evaluated in a Phase 2 trial in patients with
castration-resistant prostate cancer. In addition, Aragon
Pharmaceuticals has a selective estrogen receptor degrader (SERD) for
hormone-sensitive and hormone-resistant estrogen receptor positive
breast cancer targeted to begin clinical trials in 2013. Aragon is a
private company founded in 2009 and headquartered in San Diego,
California. For more information, visit  
www.aragonpharm.com 
Contact: 
Laura Forman 
Blueprint Life Science Group
lforman@bplifescience.com
(415) 375-3340, ext 103 
 
 
Press spacebar to pause and continue. Press esc to stop.